What is even more interesting is that prostate cancer patients with NMIBC undergoing androgen deprivation therapy or therapy with 5α-reductase inhibitors showed a similar effect of a reduced risk of recurrence when high AR protein expression was observed [49,50]. The gene discussed is AR; the disease is prostate carcinoma.